- Poster presentation
- Open access
- Published:
Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): a multi-centre, randomized, sham-controlled trial
The Journal of Headache and Pain volume 14, Article number: P184 (2013)
Introduction
Subjects who have frequent migraine attacks (≥ 2 / month) are in need of a preventive anti-migraine treatment. Available preventive drugs have incomplete efficacy and/or unpleasant side effects.
Purpose
Supraorbital transcutaneous neurostimulation (STNS) has shown encouraging results for migraine prevention in pilot studies and has no side effects [1–3]. We assessed efficacy and safety of STNS in migraine prophylaxis with the Cefaly® device in a multicentre, double-blind, randomized, sham-controlled trial.
Methods
Five Belgian tertiary headache clinics participated to the study. After a 1-month run-in, patients with ≥ 2 migraine attacks/month were randomized to verum or sham stimulation, and applied the Cefaly® device daily for 20 minutes during 3 months. Primary outcome measures were change in monthly migraine days and 50% responder rate, i.e. the percentage of subjects having a ≥ 50% reduction of monthly migraine days. Patients and enrolling neurologists were blinded from the randomization.
Results
Sixty-seven patients were randomized and included in the intention-to-treat analysis. Between run-in and 3rd month of treatment the mean number of migraine days decreased significantly in the verum (4.88 vs 6.94; p=0.023), but not in the sham group (6.22 vs 6.54; p=0.608). The 50% responder rate was significantly greater (p=0.023) in the verum (38.1%) than in the sham group (12.1 %). Monthly migraine attacks (p=0.044), monthly headache days (p=0.041) and monthly acute anti-migraine drug intake (p=0.007) were also significantly reduced in the verum but not in the sham group. There were no adverse events in either group.
Conflicts of interest
LH: Allergan. JS: ATI Redwood California, St Jude Medical USA, Allergan USA, ATI USA, Medtronic USA and Cyberonics USA.
References
Reed KL, Black SB, Banta CJ 2nd, Will KR: Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 2010, 30(3):260–271.
Solomon S, Guglielmo KM: Treatment of headache by transcutaneous electrical stimulation. Headache 1985, 25(1):12–15. 10.1111/j.1526-4610.1985.hed2501012.x
Gérardy PY, Fabry D, Fumal A, Schoenen J: A pilot study on supra-orbital surface electrotherapy in migraine. Cephalalgia 2009, 29: 134.
Mulleners WM, Chronicle EP: Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008, 28(6):585–97. 10.1111/j.1468-2982.2008.01571.x
Linde K, Rossnagel K: Propranolol for migraine prophylaxis. Cochrane database of systematic reviews (Online) 2004, (2):CD003225.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Schoenen, J., Vandersmissen, B., Jeangette, S. et al. Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): a multi-centre, randomized, sham-controlled trial. J Headache Pain 14 (Suppl 1), P184 (2013). https://doi.org/10.1186/1129-2377-14-S1-P184
Published:
DOI: https://doi.org/10.1186/1129-2377-14-S1-P184